Transgenic transchromosomal rodents for making human antibodies
US-9426970-B2 · Aug 30, 2016 · US
US10076103B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10076103-B2 |
| Application number | US-201615218202-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 25, 2016 |
| Priority date | Nov 30, 2000 |
| Publication date | Sep 18, 2018 |
| Grant date | Sep 18, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
Opening claim text (preview).
What is claimed is: 1. An isolated nucleic acid encoding the heavy and light chain variable region sequences isolated and amplified from cDNA generated from mRNA, wherein the mRNA is isolated and amplified from B lymphocytes comprising rearranged immunoglobulin sequences, wherein the rearranged immunoglobulin sequences are produced by a method comprising: providing a transgenic mouse that comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome, and obtaining the rearranged immunoglobulin sequences from the transgenic mouse. 2. An isolated nucleic acid encoding the heavy chain variable region sequence isolated and amplified from cDNA generated from mRNA, wherein the mRNA is isolated and amplified from B lymphocytes comprising rearranged immunoglobulin sequences, wherein the rearranged immunoglobulin sequences are produced by a method comprising: providing a transgenic mouse that comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome, and obtaining the rearranged immunoglobulin sequences from the transgenic mouse. 3. An isolated nucleic acid encoding the light chain variable region sequence isolated and amplified from cDNA generated from mRNA, wherein the mRNA is isolated and amplified from B lymphocytes comprising rearranged immunoglobulin sequences, wherein the rearranged immunoglobulin sequences are produced by a method comprising: providing a transgenic mouse that comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome, and obtaining the rearranged immunoglobulin sequences from the transgenic mouse. 4. A vector comprising the nucleic acid of claim 1 . 5. An expression vector comprising the nucleic acid of claim 1 in which the heavy and light chain variable regions sequences of the nucleic acid are operatively linked with a regulatory sequence that controls expression of the nucleic acid in a host cell. 6. A host cell comprising the nucleic acid of claim 1 , or progeny of the cell. 7. The host cell of claim 6 , which is a eukaryote. 8. A method of producing a human antibody display library, comprising: introducing an immunogen into a transgenic mouse, wherein the transgenic mouse comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome; isolating a population of nucleic acids encoding human antibody chains from lymphatic cells of the transgenic mouse; and forming a library of display packages displaying the antibody chains, wherein a library member comprises a nucleic acid encoding an antibody chain displayed from the package. 9. The method of claim 8 , wherein the transgenic mouse lacks a detectable titer to the immunogen when the isolating is performed. 10. The method of claim 8 , wherein the immunogen is encoded by a nucleic acid. 11. The method of claim 10 , wherein the nucleic acid encodes a membrane bound receptor.
Knock-out vertebrates · CPC title
comprising antibodies · CPC title
against CD4 · CPC title
for producing genetically modified animals, e.g. transgenic · CPC title
Animal expressing industrially exogenous proteins · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.